<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02145637</url>
  </required_header>
  <id_info>
    <org_study_id>4-2013-0405</org_study_id>
    <nct_id>NCT02145637</nct_id>
  </id_info>
  <brief_title>Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase Ib study will investigate dose limiting toxicity (DLT) and maximum tolerated dose&#xD;
      (MTD) of afatinib and ruxolitinib combination therapy, based on the preclinical data that&#xD;
      inhibition of IL-6R/JAK1 signal transmission pathway will increase sensitivity to afatinib.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 7, 2015</start_date>
  <completion_date type="Actual">November 9, 2017</completion_date>
  <primary_completion_date type="Actual">November 9, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To set a recommended phase II dose (RP2D)</measure>
    <time_frame>36 days</time_frame>
    <description>We will set a recommended phase II dose (RP2D) using conventional 3+3 deisgn.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability (dose relating toxicity; DLT)</measure>
    <time_frame>1year</time_frame>
    <description>Adverse events (AEs) will be assessed according to NCI common toxicity criteria (CTC) version 4.03.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>1year</time_frame>
    <description>Response and progression will be evaluated in this study using modified international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>1year</time_frame>
    <description>PFS will be defined as the start of the treatment to the first occurrence of progression, relapse, or death from any cause as assessed by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>1year</time_frame>
    <description>OS will be defined as the start of the treatment to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic biomarker</measure>
    <time_frame>1year</time_frame>
    <description>The biomarkers marker related with EGFR and JAK/STAT pathway as well as gene analysis, using peripheral blood mononuclear cell(PBMC), circulating tumor cell (CTC) and skin and tumor tissue sample will be analyzed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>Afatinib plus Ruxolitinib combination (single arm)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib plus Ruxolitinib combination therapy</intervention_name>
    <arm_group_label>Afatinib plus Ruxolitinib combination (single arm)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Stage 4 NSCLC patients&#xD;
&#xD;
          2. disease progression after platinum doublet (all), EGFR TKI (if EGFR mutant), and&#xD;
             crizotinib (if ALK positive)&#xD;
&#xD;
          3. Men and women aged 20 years or older&#xD;
&#xD;
          4. Recovery from previous drug-related toxicity: CTCAE 4.03 â‰¤ Grade 1&#xD;
&#xD;
          5. ECOG 0 or 1&#xD;
&#xD;
          6. able to orally take and retain drug&#xD;
&#xD;
          7. have a measurable or unmeasurable lesion under RECIST 1.1 Criteria&#xD;
&#xD;
          8. have proper hematological, renal, and hepatic functions&#xD;
&#xD;
          9. intention to use an acceptable contraception&#xD;
&#xD;
         10. able to read and understand the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. previous chemotherapy, radiation therapy, immunotherapy, or other anticancer therapy&#xD;
             within 14 days&#xD;
&#xD;
          2. Clinically significant gastrointestinal disorder or malabsorption syndrome&#xD;
&#xD;
          3. Acute digestive disorder&#xD;
&#xD;
          4. major organ failure&#xD;
&#xD;
          5. Significant cardiac disorders&#xD;
&#xD;
          6. major operation of a main organ in 4 weeks&#xD;
&#xD;
          7. Untreated symptomatic brain metastasis&#xD;
&#xD;
          8. pregnant or nursing&#xD;
&#xD;
          9. previously diagnosed Interstitial lung disease(ILD)&#xD;
&#xD;
         10. previously treated with irreversible pan-HER inhibitor including Afatinib or&#xD;
             Ruxolitinib&#xD;
&#xD;
         11. previously experienced hypersensitivity to an ingredient of the study drug&#xD;
&#xD;
         12. must receive CYP3A4 inducer or inhibitor persistently during the study period.&#xD;
&#xD;
         13. HIV positive or active hepatitis&#xD;
&#xD;
         14. threatening patient's safety is predicted&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>April 23, 2014</study_first_submitted>
  <study_first_submitted_qc>May 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2014</study_first_posted>
  <last_update_submitted>March 27, 2019</last_update_submitted>
  <last_update_submitted_qc>March 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer, Lung cancer, Head and neck squamous cell carcinoma, Afatinib, Ruxolitinib, EGFR, JAK, STAT</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Afatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

